Piaopiao Li
Overview
Explore the profile of Piaopiao Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li P, Ali M, Narayan K, Umpierrez G, Fonseca V, Shi L, et al.
Diabetes Care
. 2025 Jan;
PMID: 39841556
No abstract available.
2.
Alkhuzam K, Li P, Abuloha S, Xue Q, Shi L, Fonseca V, et al.
Diabetes Obes Metab
. 2025 Jan;
27(3):1564-1571.
PMID: 39778035
Objective: Time in range (TIR) is an important metric to measure variability of blood glucose levels. The aim is to quantify the long-term health benefits and economic return associated with...
3.
Li P, Li Z, Staton E, Umpierrez G, Davis G, Shao H, et al.
JAMA
. 2024 Oct;
332(19):1667-1669.
PMID: 39441612
No abstract available.
4.
Li P, Spector E, Alkhuzam K, Patel R, Donahoo W, Bost S, et al.
Diabetes Obes Metab
. 2024 Sep;
27(1):102-110.
PMID: 39344840
Aim: To develop an automated computable phenotype (CP) algorithm for identifying diabetes cases in children and adolescents using electronic health records (EHRs) from the UF Health System. Materials And Methods:...
5.
Alshehri A, Guan D, Li P, Zhang Y, Ghayee H, Jiao T, et al.
Prim Care Diabetes
. 2024 Aug;
18(5):561-563.
PMID: 39095227
Background: The newer glucose-lowering drugs (GLDs), including Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), have demonstrated superior cardio- and renal protective benefits compared to older GLDs in...
6.
Li P, Kianmehr H, Guan D, Kulshreshtha A, Narayan K, Ali M, et al.
Diabetes Obes Metab
. 2024 Jul;
26(9):3958-3968.
PMID: 38962812
Aim: Dysglycaemia accelerates cognitive decline. Intensive glucose control may help delay or prevent cognitive function decline (CFD). We aimed to determine how patient characteristics influence the effect of intensive glucose...
7.
Li P, Alkhuzam K, Brown J, Zhang Y, Jiao T, Guo J, et al.
Diabetes Obes Metab
. 2024 Jun;
26(9):3723-3731.
PMID: 38899435
Aim: To examine the associations between low cognitive performance (LCP) and diabetes-related health indicators (including body mass index [BMI], HbA1c, systolic blood pressure [SBP], low-density lipoprotein [LDL] and self-reported poor...
8.
Jiao T, Kianmehr H, Lin Y, Li P, Ospina N, Ghayee H, et al.
Diabetes Obes Metab
. 2024 Feb;
26(4):1502-1509.
PMID: 38297986
Aim: The action to control cardiovascular risk in diabetes (ACCORD) trial showed a neutral average treatment effect of intensive blood glucose and blood pressure (BP) controls in preventing major adverse...
9.
Wang G, Li P, Wang Y, Guo J, Wilson D, Lo-Ciganic W
J Clin Med
. 2023 Oct;
12(19).
PMID: 37834986
Depression, commonly treated with antidepressants, is associated with an increased risk of dementia, especially in older adults. However, the association between antidepressant use and dementia risk is unclear. We searched...
10.
Li P, Lyu T, Alkhuzam K, Spector E, Donahoo W, Bost S, et al.
J Am Med Inform Assoc
. 2023 Oct;
31(1):165-173.
PMID: 37812771
Objective: Having sufficient population coverage from the electronic health records (EHRs)-connected health system is essential for building a comprehensive EHR-based diabetes surveillance system. This study aimed to establish an EHR-based...